ClinicalTrials.gg
Not yet recruitingNCT07081815Updated Sep 2, 2025

JOCOAT Safety and Tolerability Clinical Trial GLAD-04

An interventional study of JOCOAT(TM) APN-3003 in Surgical Adhesions, sponsored by ARC Medical Inc.. Not yet recruiting. Open to participants aged 15 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by ARC Medical Inc. · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
15 Years to 25 Years
Sex
All
01

Study summary

This study will assess the safety and efficacy of a new liquid anti-adhesion device, JOCOAT(TM) APN-3003 in patients undergoing knee anterior cruciate ligament reconstruction (ACLR) surgery.

This is a single-center, prospective study. Safety and clinical outcomes will be compared with historical controls from enrolled study site patients from NCT03935750 (STABILITY 2) which has evaluated outcomes following ACL rupture in young athletes.

A maximum of 24 patients aged 15-25 years undergoing primary anatomic ACLR with quadriceps tendon (QT) graft following a standardized surgical treatment algorithm will be enrolled. All patients will receive JOCOAT(TM) APN-3003 at the end of their surgery.

02

Conditions studied

  • Surgical Adhesions

Browse trials for

03

In context

Tissue Adhesions

121 studies on the registry are indexed under Tissue Adhesions; 15 are open to participants now.

This study's planned enrollment of 24 is below the median of 61 across 84 interventional studies indexed under Tissue Adhesions.

Browse Tissue Adhesions studies →

Lead sponsor

This is the only study on the registry with ARC Medical Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Pre-operative Inclusion Criteria:

  • Understand and be able to follow the requirements of the protocol including personally signing and dating an REB approved Form prior to undergoing any protocol related procedures
  • Subjects aged 15 to 25 years with an ACL-deficient knee undergoing primary ACLR
  • Subjects with skeletal maturity (i.e. closed epiphyseal growth plates on standard knee radiographs)
  • At least two of the following factors that are associated with a high risk of graft failure:

    1. participate in a competitive pivoting sport (defined as sports that include cutting and pivoting activities such as basketball, American football, soccer, lacrosse, volleyball, tennis/squash, handball, downhill skiing etc);
    2. have a pivot shift of grade 2 or greater;
    3. have generalized ligamentous laxity (Beighton score of >= 4) and/or genu recurvatum > 10 degrees
  • Biological females have a negative pregnancy test within 4 days of initial surgery
  • Is willing, able and likely to fully comply with clinical trial procedures and restrictions including follow-ups

Pre-operative Exclusion Criteria:

  • Simultaneous bilateral ACLR
  • Previous ACLR on either knee
  • Less than one year from contralateral knee or contralateral/ipsilateral hip/ankle surgery
  • Prior arthrotomy in the study knee
  • Active infection anywhere or previous infection in the study knee
  • History of peri-articular fracture in study knee
  • > 3 degrees of asymmetric varus or valgus
  • The patient has debilitating knee pain that would preclude the use of tissue as a graft
  • The patient has a significant quad tendonitis that would preclude the use of QT tissue as a graft
  • Known or suspected allergy to brown seaweed, seaweed-based materials such as fucoidan, food allergies and/or presence of any allergy related dietary restrictions unless deemed by the investigator as "Not "
  • Known or suspected allergy to fucose, galactose, sulfur, sulfate, sulfite, or any sugar-based polymer or polysaccharides containing these
  • Known to sodium lactate or sulfur-containing compounds
  • Any other severe allergic conditions or previous reactions (e.g., anaphylactic reactions, angioedema)
  • Severe metabolic acidosis or alkalosis
  • Have insulin dependent diabetes, severe diabetes and/or poorly controlled diabetes mellitus
  • Any general medical or surgical condition that would preclude a standard knee ACLR
  • Inflammatory arthropathy
  • Breast feeding
  • Have a medical condition that, in the opinion of the investigator would interfere with the evaluation of the safety or efficacy of the product
  • Have received any investigational products that, in the opinion of the investigator, would interfere with the evaluation of the safety or efficacy of the investigational product
  • Have clinically relevant hemochromatosis, hepatic, renal, , lymphatic, hematological or coagulation disorders
  • Family history of blood or coagulation disorders
  • History of heparin-induced thrombocytopenia (HIT) or known sensitivity to heparin-like products

Intra-operative Inclusion Criteria:

- Patient undergoes primary anatomic anterior cruciate ligament reconstruction surgery with quadriceps tendon (QT) graft

Intra-operative Exclusion Criteria:

  • Pre-existing arthrofibrosis in the knee
  • Partial ACL rupture (defined as one bundle ACL tear requiring reconstruction/ augmentation of the torn bundle with no surgery required for the intact bundle) where ACLR is not performed
  • Multiple ligament injury (two or more ligaments requiring surgery)
  • Symptomatic articular cartilage defect requiring treatment other than debridement
  • Articular cartilage lesion that requires any other surgical treatment apart from debridement
  • Under anesthetic, this patient has a symmetrical or grade 1 pivot shift AND has a Beighton score \<4 AND \<10 degrees hyperextension
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    JOCOAT(TM) APN-3003

    Intra-articular injection

    Device: JOCOAT(TM) APN-3003

Interventions

  • DeviceJOCOAT(TM) APN-3003

    10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery

06

What researchers measure

Primary outcomes

  1. Safety of JOCOAT(TM) APN-3003 as measured by number and severity of adverse device effects and serious adverse device effects

    The number of severe and serious adverse events in treated subjects from this study is compared with the number seen in historical controls

    Time frame: 3 months after surgery

Secondary outcomes

  1. Exploratory efficacy of JOCOAT(TM) APN-3003 as measured by comparing range of motion (ROM) pre-operatively and post-operatively

    Range of motion is measured pre-operative and post-operatively and compared

    Time frame: 3 months after surgery

  2. Patient recovery as measured by Patient Reported Outcome Measures (KOOS)

    Patient reported outcome measure results (Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire) pre-operatively and post-operatively are compared with historical controls

    Time frame: Up to 12 months after surgery

  3. Patient recovery as measured by Patient Reported Outcome Measures (PASS)

    Patient reported outcome measure results (Patient-Acceptable Symptom States (PASS) questionnaire) pre-operatively and post-operatively are compared with historical controls

    Time frame: Up to 12 months after surgery

  4. Patient recovery as measured by Patient Reported Outcome Measures (EQ-5D-5L)

    Patient reported outcome measure results (EQ-5D-5L questionnaire) pre-operatively and post-operatively are compared with historical controls

    Time frame: Up to 12 months after surgery

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Aug 2026, 11 months later.

Of 35 interventional studies with no phase under Tissue Adhesions, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 23, 2025
StartEst.
Sep 2025
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07081815
Lead sponsor
ARC Medical Inc.
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Sep 2025 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion